TESARO (TSRO) Misses Q4 EPS by 96c, Guides Revenue Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
February 27, 2018 4:05 PM ESTZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S.2017 ZEJULA® net sales totaled $109 million during first nine months of commercial launchFocused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settingsMultiple immuno-oncology clinical studies to read out in 2018Enrollment of registration trial of TSR-042 (anti-PD-1 mAb) to complete by YE 2018
WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical... More
